Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus ENOVID E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus ENOVID E.
ARANELLE vs ENOVID-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive